Literature DB >> 17426976

Serum pro-matrix metalloproteinase-3 as an indicator of disease activity and severity in rheumatoid arthritis: comparison with traditional markers.

Aşkin Ateş1, Nuran Türkçapar, Umit Olmez, Olcay Tiryaki, Nurşen Düzgün, Emre Uğuz, Murat Duman.   

Abstract

Matrix metalloproteinase-3 (MMP-3) production increases in rheumatoid arthritis (RA) and has been proposed as a marker of disease activity and joint damage. The aim of this cross-sectional study is to examine the usefulness of serum proMMP-3 as an indicator of disease activity and severity in comparison with erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Serum proMMP-3 was measured by a quantitative ELISA in 85 RA patients and 70 healthy subjects. Clinical and laboratory measures of disease activity and severity were obtained. Radiological joint damage was assessed by the method of Larsen. Serum proMMP-3 was significantly higher in RA patients than that in the healthy subjects. The active RA patients had significantly higher serum proMMP-3 than the inactive patients. Serum proMMP-3 was significantly correlated with some parameters of disease activity including swollen joints count, proximal interphalangeal joint score, morning stiffness, and Health Assessment Questionnaire; however, ESR and serum CRP were better correlated with all indicators of the disease activity than proMMP-3. The analysis of receiver operating characteristic supported that ESR and CRP had higher performance for reflection of activity compared to proMMP-3. There were no significant associations among Larsen score and proMMP-3, ESR, and CRP. Our results suggest that the cross-sectional measurement of serum proMMP-3 could not give additional information about RA disease activity compared to ESR and CRP, and could not give any information about joint damage.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17426976     DOI: 10.1007/s00296-007-0338-1

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   3.580


  34 in total

Review 1.  The search for laboratory measures of outcome in rheumatoid arthritis.

Authors:  F A Wollheim; K B Eberhardt
Journal:  Baillieres Clin Rheumatol       Date:  1992-02

2.  Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis.

Authors:  G Cunnane; O Fitzgerald; C Beeton; T E Cawston; B Bresnihan
Journal:  Arthritis Rheum       Date:  2001-10

3.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

4.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

5.  Serum MMP-3 in rheumatoid arthritis: correlation with systemic inflammation but not with erosive status.

Authors:  A So; A M Chamot; V Péclat; J C Gerster
Journal:  Rheumatology (Oxford)       Date:  1999-05       Impact factor: 7.580

6.  Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression.

Authors:  M D Posthumus; P C Limburg; J Westra; M A van Leeuwen; M H van Rijswijk
Journal:  J Rheumatol       Date:  2000-12       Impact factor: 4.666

7.  Connective tissue metabolism in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity, bone mineral density, and radiographic outcome.

Authors:  Trine Jensen; Mette Klarlund; Michael Hansen; Karl Erik Jensen; Henrik Skjødt; Lars Hyldstrup
Journal:  J Rheumatol       Date:  2004-09       Impact factor: 4.666

8.  Serum matrix metalloproteinase 3 levels in comparison to C-reactive protein in periods with and without progression of radiological damage in patients with early rheumatoid arthritis.

Authors:  M D Posthumus; P C Limburg; J Westra; M A van Leeuwen; M H van Rijswijk
Journal:  Clin Exp Rheumatol       Date:  2003 Jul-Aug       Impact factor: 4.473

9.  Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis.

Authors:  Y Ichikawa; C Yamada; T Horiki; Y Hoshina; M Uchiyama
Journal:  Clin Exp Rheumatol       Date:  1998 Sep-Oct       Impact factor: 4.473

10.  Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis.

Authors:  I Tchetverikov; L R Lard; J DeGroot; N Verzijl; J M TeKoppele; F C Breedveld; T W J Huizinga; R Hanemaaijer
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

View more
  3 in total

1.  Stachys schtschegleevii tea, matrix metalloproteinase, and disease severity in female rheumatoid arthritis patients: a randomized controlled clinical trial.

Authors:  Elham Mirtaheri; Alireza Khabbazi; Hossein Nazemiyeh; Ali-Asghar Ebrahimi; Mehrzad Hajalilou; Zahra Shakibay Novin; Saeed Pirouzpanah
Journal:  Clin Rheumatol       Date:  2021-11-11       Impact factor: 2.980

2.  Interferon-gamma inhibits interleukin-1beta-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis.

Authors:  Charlotte E Page; Shaun Smale; Sara M Carty; Nicholas Amos; Sarah N Lauder; Rhian M Goodfellow; Peter J Richards; Simon A Jones; Nicholas Topley; Anwen S Williams
Journal:  Arthritis Res Ther       Date:  2010-03-22       Impact factor: 5.156

3.  Alteration of matrix metalloproteinase-3 O-glycan structure as a biomarker for disease activity of rheumatoid arthritis.

Authors:  Masaru Takeshita; Atsushi Kuno; Katsuya Suzuki; Atsushi Matsuda; Hiroko Shimazaki; Tomomi Nakagawa; Yuki Otomo; Yasuaki Kabe; Makoto Suematsu; Hisashi Narimatsu; Tsutomu Takeuchi
Journal:  Arthritis Res Ther       Date:  2016-05-21       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.